BioTissue Holdings announced in a press release the completion of the sale of its non-ocular surgical and wound care business to BioStem Technologies. Under the agreement, BioStem will acquire exclusive rights to the Neox and Clarix product lines. BioTissue’s surgical sales team and key support staff will join BioStem’s commercial organization, while BioTissue will continue manufacturing these products for BioStem. 

BioTissue said it will concentrate its commercial strategy on advancing interventional therapies for acute and chronic ocular surface conditions, including Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard, while prioritizing product innovation, professional education, and comprehensive customer support for the eyecare market.

“Since our founding, our mission has been to transform patient outcomes through regenerative therapies,” said Ted Davis, president and CEO of BioTissue, in the press release. “This divestiture is a catalyst for our next chapter, one focused squarely on eyecare innovation."